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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of nigral 
dopaminergic neurons innervating the striatum, the main input structure of the basal ganglia. 
This creates an imbalance between dopaminergic inputs and cholinergic interneurons (ChIs) 
within the striatum. The efficacy of anticholinergic drugs, one of the earliest therapy for PD 
before the discovery of L-3,4-dihydroxyphenylalanine (L-DOPA) suggests an increased 
cholinergic tone in this disease. The dopamine (DA)-acetylcholine (ACh) balance hypothesis is 
now revisited with the use of novel cutting-edge techniques (optogenetics, pharmacogenetics, new 
electrophysiological recordings). This review will provide the background of the specific contribution 
of ChIs to striatal microcircuit organization in physiological and pathological conditions. The second 
goal of this review is to delve into the respective contributions of nicotinic and muscarinic 
receptor cholinergic subunits to the control of striatal afferent and efferent neuronal systems. 
Special attention will be given to the role played by muscarinic acetylcholine receptors (mAChRs) in 
the regulation of striatal network which may have important implications in the development of novel 
therapeutic strategies for motor and cognitive impairment in PD. 
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Introduction 
The striatum is the most prominent nucleus of the basal ganglia circuitry controlling goal-directed 
action selection, habit learning and motivational processes (Pisani et al., 2007; Schultz, 2002). Striatal 
activity is mainly driven by excitatory glutamatergic cortical and thalamic afferents as well as 
modulatory dopaminergic (DA) afferents from the midbrain (Bolam et al., 2000; Gerfen and Surmeier, 
2011; Kreitzer and Malenka, 2008; Tepper et al., 2007). Progressive degeneration of DA neurons in 
the substantia nigra pars compacta (SNc) is known to be the major neuropathological characteristic of 
Parkinson’s disease (PD), although recent studies highlight the degeneration of serotonergic, 
noradrenergic, cholinergic and glutamatergic neuronal systems during the course of the disease 
(Brichta et al., 2013; Hung and Schwarzschild, 2014; Moghaddam et al., 2017). This produces major 
changes in the striatal microcircuits and in the projection neurons of the striatum, named medium 
spiny neurons (MSNs), representing 90-95% of the striatal neuronal population. The remaining 5-10% 
of striatal neurons are interneurons, which are crucial regulators of MSNs and afferents to the striatum. 
Among them, cholinergic interneurons (ChIs) closely interact with the midbrain DA afferents in a 
dynamic balance.  Despite being few in numbers, ChIs modulate MSNs activity and control 
neuronal afferents by extensive ramifications and widespread projections throughout the 
striatum (Phelps et al., 1985). Disruption of ChIs activity often leads to the basal ganglia-related 
movement disorders such as PD, dystonia and Tourette syndrome (Deffains and Bergman, 2015; 
Gonzales and Y. Smith, 2015; Pisani et al., 2007; Tanimura et al., 2018). PD is well-characterized by 
its motor symptomatology (akinesia, rigidity and tremor at rest), but may also be associated with mood 
disorders and cognitive impairment (Chaudhuri et al., 2006; Obeso et al., 2000). Striatal ChIs appear 
to be important contributors to affective, attentional, motivational, synaptic plasticity and cognitive 
functions mediated by the dorsal striatum (Aarsland, 2016; Bohnen and Albin, 2011; Calabresi et al., 
2006; Chaudhuri et al., 2006; Deffains and Bergman, 2015; Owen et al., 1993). Considering that ChIs, 
in close interaction with the dopaminergic system, play a key regulatory role in motor function, in 
physiological and pathological conditions (Acquas and Di Chiara, 2002; Aosaki et al., 2010; Di Chiara 
et al., 1994; Gittis and Kreitzer, 2012; Lester et al., 2010; Rizzi and Tan, 2017), their involvement in 
non-motor symptoms of PD remains an important question.  
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The prevailing view of DA-ACh interactions in the striatum supports the idea that the cholinergic and 
dopamine systems exert opposing actions to produce movement, and that unbalanced interactions are 
observed in pathological condition (Aosaki et al., 2010). This was supported by preclinical studies 
in PD models demonstrating that striatal dopamine depletion leads to increased ChIs excitability in 
vitro (Fino et al., 2007; Maurice et al., 2015), synaptic reorganization of striatal ChIs within the 
striatum (Salin et al., 2009; Tozzi et al., 2016) and increased release of striatal ACh (Bonsi et al., 
2011; DeBoer et al., 1993; Pisani et al., 2007). The DA-ACh balance hypothesis was also supported 
by clinical evidence showing improvement of parkinsonian tremor and rigidity by both DA 
agonists and anticholinergic drugs (Barbeau, 1962). Within the striatum, these two 
neurotransmitters exhibit coincident changes in their activity during behavior (Apicella, 2007; Morris 
et al., 2004) and exert reciprocal control on their release (Cragg, 2006; DeBoer and Abercrombie, 
1996; Pisani et al., 2000; Threlfell et al., 2012). However, this competition, and sometimes 
cooperation, between the two systems has been revisited in light of the major role played by 
thalamostriatal connections on striatal microcircuits and synaptic rearrangements in PD and the 
complexity of the receptors involved in these regulations (Parker et al., 2016; Surmeier and 
Graybiel, 2012; Threlfell et al., 2012). Although cholinergic tone increases as striatal DA level 
decline, the mechanisms underlying this alteration are still unclear. This review will focus on the 
specific interaction between striatal ChIs and DA systems and the mechanisms underlying the 
regulation of striatal and basal ganglia function in physiological and pathophysiological state, in light 
of the recent results obtained with novel technologies and selective cholinergic receptor subtypes 
drugs, with a specific emphasis on muscarinic acetylcholine receptors (mAChRs) subtypes. The 
complexity of the mechanisms by which ACh modulates striatal microcircuit in physiological 
condition and its implication for PD has been recently addressed in different reviews (Abudukeyoumu 
et al., 2018; Conti et al., 2018; Girasole and Nelson, 2018; Tanimura et al., 2018). 
 
Cholinergic interneurons in the striatal microcircuitry 
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ChIs represent approximately 1-2% of striatal neurons (Bolam et al., 1984; Kemp and Powell, 1971; 
Phelps et al., 1985) and were first identified in 1896 by Kölliker on the basis of choline 
acetyltransferase immunolabeling (ChAT, the ACh synthesizing enzyme) and acetylcholinesterase 
(AChE, the ACh degrading enzyme). Despite a recent tract tracing and electron microscopy study 
reporting an external cholinergic projection from the brainstem into the striatum (Dautan et al., 2014), 
ChIs are still considered the main source of acetylcholine (ACh) within the striatum (Phelps et al., 
1985; Satoh et al., 1983; Woolf and Butcher, 1981). Anatomically, they are easily characterized from 
other striatal cell types by their large spherical soma (20-50 μm of diameter) and widespread dendritic 
and axonal arborizations (Bolam et al., 1984). ChIs are heterogeneously distributed within the striatum 
with a preferential distribution at the border between striosomes and extra-striosomal matrix (van 
Vulpen and van der Kooy, 1998). 
Referred to as giant aspiny interneurons, striatal ChIs send projections widely throughout the striatum, 
leading to high levels of cholinergic markers (ChAT and AChE) in the striatum. ChIs axons are 
characterized by small varicosities; it is estimated that each ChI possesses an average of 500,000 
varicosities (Contant et al., 1996). In contrast to the dense striatal cholinergic innervation, few 
cholinergic synapses have been found (Aznavour et al., 2003; Contant et al., 1996), suggesting that 
ACh, in addition to synaptic transmission, acts also via non-synaptic transmission (volumetric 
transmission) released by these varicosities (Descarries et al., 1997; Havekes et al., 2011). 
Electrophysiological characteristics of ChIs are distinct from MSNs and GABAergic interneurons 
during in vivo recordings. In contrast to other striatal neuronal populations, ChIs fire spontaneously 
even in the absence of synaptic activity. This particular autonomous pacemaker activity led them to be 
referred to ‘tonically active neurons’ (TANs) (Aosaki et al., 1995; Tepper and Bolam, 2004; Wilson et 
al., 1990). In vitro electrophysiological recordings show that ChIs display tonic action potential firing 
(2-10 Hz) (Bennett and Wilson, 1999), depolarized resting membrane potential (-60 mV) (Lee et al., 
1998), long-lasting action potential (Kawaguchi, 1993), high input resistance (200 MΩ), slow spike 
afterhyperpolarization current (Goldberg and Wilson, 2005), and prominent hyperpolarization-
activated cation current (Ih) (Deng et al., 2007). 
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ChIs have a wide range of effects in the striatum mediated by two types of receptors, metabotropic 
muscarinic ACh receptors (mAChRs) and ionotropic nicotinic ACh receptors (nAChRs). These two 
types of receptors are expressed by ChIs, MSNs, as well as corticostriatal and thalamostriatal 
glutamatergic terminals, and nigrostriatal dopaminergic terminals. As illustrated in Fig. 1, the diversity 
of mAChRs and nAChRs and their localization highlights the complexity of striatal connectivity 
(Bonsi et al., 2011; Conti et al., 2018; Kreitzer, 2009; Lim et al., 2014; Pisani et al., 2007).  
Five distinct G-protein-coupled mAChRs (M1-M5) are divided into two main classes according to 
their pharmacological properties and transduction mechanisms (Wess et al., 2007): M1-like (M1, M3, 
and M5) and M2-like (M2 and M4). M1-like receptors are coupled to Gq/11 proteins, intracellular 
Ca
2+ 
mobilization, phospholipase C and protein kinase C activation, whereas M2-like receptors are 
coupled to Gi/o proteins, reduce cAMP formation and inhibit Ca
2+
 channels (Kreitzer, 2009). 
Interestingly, the activation of mAChRs has been shown to result in both excitation and inhibition of 
cholinergic, dopaminergic, GABAergic and glutamatergic activities in the striatum, suggesting a 
complex modulatory role of mAChRs involving numerous subtypes at multiple pre- or postsynaptic 
levels (Conti et al., 2018; Pisani et al., 2007). Several receptor localization studies in rodents report a 
predominant expression of M4 mAChRs within the striatum (45% of total striatal mAChRs) whereas 
M1 and M2 mAChRs are expressed at 30% and 20% of total striatal mAChRs, respectively (Chapman 
et al., 2011; Volpicelli and Levey, 2004; Waelbroeck et al., 1990; Yasuda et al., 1993). M3 mAChRs 
are clearly less abundant and M5 mAChRs are expressed at a very low level (Chapman et al., 2011; 
Hersch and Levey, 1995; Weiner et al., 1990; Yasuda et al., 1993). 
nAChRs constitute the second type of cholinergic receptors. They are ligand-gated ion channels 
composed of five subunits that are assembled into homomeric or heteromeric subunits combinations, 
which determine pharmacological characteristics and biophysical properties of the receptors (Dani, 
2001). Different subtypes of nAChRs composed of α4, α6, α7, β2, and β3 subunits are the most 
expressed in the striatum, with a predominant expression of α4β2 and α6β2 subunits combination, 
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with other subunits present at lower levels (Quik et al., 2007; Quik and Wonnacott, 2011; Zhou et al., 
2002). nAChRs are expressed on glutamatergic and dopaminergic neuron terminals, fast-spiking 
GABAergic interneurons (English et al., 2011; Nelson et al., 2014) and ChIs, but are absent from 
MSNs (Quik et al., 2007). They can be expressed both pre- and post-synaptically, where they induce 
depolarization and increase excitability and thus glutamate, DA and GABA release (Brichta et al., 
2013; Koós and Tepper, 2002; Rice et al., 2011; Zhou et al., 2001).  
Despite that both types of acetylcholine receptors transduce ACh signals, mAChRs are highly 
expressed by axon terminals of all major afferents to the striatum (glutamatergic and dopaminergic 
terminals) and by all striatal neurons examined so far, primarily in ChIs and in MSNs (Goldberg et al., 
2012; Kreitzer, 2009; Zhou et al., 2003) as illustrated in Fig. 1. Activation of mAChRs results in a 
slower, but potentially more sustained response (Lester et al., 2010). The part played by mAChRs in 
the regulation of striatal network is the main focus of this review. Excellent reviews about the 
involvement of nAChRs in the regulation of striatal circuit complement the topics broached here 
(Abudukeyoumu et al., 2018; Conti et al., 2018; Cragg, 2006; Gonzales and Y. Smith, 2015; Threlfell 
and Cragg, 2011; Zhou et al., 2003; 2002). 
 
Muscarinic modulation of cholinergic interneurons 
M2 and M4 mAChRs, coupled to Gi/o proteins, are expressed presynaptically in ChIs where they act 
as autoreceptors which exert a negative feedback control on ACh release (Calabresi et al., 2000; 
1998a; J. J. Ding et al., 2006; Oldenburg and J. B. Ding, 2011; Pisani et al., 2007; Yan and Surmeier, 
1996). A relatively selective antagonist of M2 mAChRs, AF-DX 116, induces a net increase of ACh 
release in the striatum by blocking negative feedback control (Galarraga et al., 1999). Using M2 or M4 
mAChRs-knockout mice or even double M2/M4-knockout mice, a study showed that deletion of M2 
mAChRs does not affect ACh release whereas deletion of M4 mAChRs completely suppresses the 
inhibitory control on ACh release in the striatum (Zhang et al., 2002). These data indicate that M4 
mAChRs expressed in ChIs rather than M2 mAChRs play a critical role in the negative feedback 
control of ACh release within the striatum. 
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Muscarinic modulation of MSNs 
M1 mAChRs are expressed in both direct and indirect MSNs, while M4 mAChRs are mainly 
expressed in direct MSNs (Bonsi et al., 2011; Ince et al., 1997; Pisani et al., 2007). Indeed, a study 
investigated their distribution and reported that M4 mAChRs are found in 86% of direct MSNs and 
14% of indirect MSNs (Santiago and Potter, 2001). M1 mAChRs are coupled to Gq proteins that 
activate phospholipase C resulting in activation of inositol trisphosphatase and diacyl-glycerol, 
ultimately increasing intracellular Ca
2+
 (Pisani et al., 2007). The pharmacological blockade of 
M1 mAChRs with the selective antagonist, telenzepine, thus produces a reduction of activity in 
the two striatal output pathways (Ztaou et al., 2016). Several studies suggest that the activation of 
M1 mAChRs enhances NMDA-receptor mediated currents, promoting MSNs depolarization and 
corticostriatal long-term potentiation (Bonsi et al., 2011; Calabresi et al., 1999; 1998b; Oldenburg and 
J. B. Ding, 2011). 
M4 mAChRs activate Gi/o proteins and their activation results, among other mechanisms, in 
Cav2 channel inhibition and therefore shapes the spiking of direct MSNs (Santiago and Potter, 
2001; Pisani et al., 2007).  
 
Muscarinic modulation of GABAergic interneurons 
GABAergic interneurons express predominantly M1 mAChRs and to a lesser extent M2 and M4 
mAChRs (Kreitzer, 2009). Electrophysiological data show that the nonselective mAChRs agonist, 
muscarine, decreases GABA release, suggesting that M2 and M4 mAChRs are predominantly 
expressed by GABAergic interneurons and involved in inhibition of GABA release (Kreitzer, 2009). 
 
Muscarinic modulation of glutamatergic terminals 
M2 and M3 mAChRs are both expressed on glutamatergic corticostriatal afferents where they exert 
opposite effects either by inhibiting or facilitating glutamate release, respectively (Alcantara et al., 
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2001; Higley et al., 2009; Pisani et al., 2007). Overall, scopolamine, a nonselective mAChRs 
antagonist, has been shown to increase the extracellular glutamate concentration within the striatum 
(Rawls and McGinty, 1998). The contribution of mAChRs to the regulation of the glutamatergic 
thalamostriatal connections remains unknown and will greatly benefit from delineation of the 
respective contributions of corticostriatal and thalamostriatal inputs to the synaptic rearrangements in 
pathological condition. 
 
Muscarinic modulation of dopaminergic terminals 
Dopaminergic nerve terminals express M4 mAChRs and their activation induces a decrease of DA 
release. In vitro studies using striatal slices or striatal synaptosomes show that activation of mAChRs 
from dopaminergic terminals increases ACh release (Bonanno et al., 1985; Lehmann and Langer, 
1982). Conversely, in vivo microdialysis studies revealing that local injection of mAChRs agonists and 
antagonists may either increase, decrease, or have no effect on DA release (Meltzer et al., 1994; 
Smolders et al., 1997; Westerink et al., 1990; Whitehead et al., 2001; Xu et al., 1989). These data are 
contradictory, however the diversity of cholinergic receptors subtypes could be partially responsible 
for the different effects on DA release. This also might be explained by the fact that muscarinic 
modulation of dopaminergic terminals is only a minor contribution to the cholinergic regulation of 
striatal activity compared to nicotinic receptor modulation. 
 
Functional dysregulation of cholinergic interneurons in Parkinson’s disease 
The classical view of basal ganglia functional organization posits that two pathways control basal 
ganglia output structures. Direct pathway MSNs project to globus pallidus internal segment (GPi) and 
substantia nigra pars reticulata (SNr), and preferentially express DA D1 receptors. Indirect pathway 
MSNs that project indirectly to GPi/SNr via the globus pallidus external segment (GPe) and the 
subthalamic nucleus (STN) and preferentially express the DA D2 receptors (Albin et al., 1989; 
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Alexander and Crutcher, 1990; Bolam et al., 2000; DeLong, 1990; Gerfen et al., 1990; A. D. Smith 
and Bolam, 1990). The direct pathway promotes the initiation of movement by transiently interrupting 
the tonic inhibitory GPi/SNr effect on the thalamocortical pathway and brainstem targets while the 
indirect pathway inhibits movement. However, recent studies challenge this view by showing that both 
pathways may be concurrently active during movements (Calabresi et al., 2014; Tecuapetla et al., 
2014). 
In PD, the degeneration of DA neurons in the SNc induces a reduction of DA levels within the 
striatum and creates an imbalance between the activity in the direct and indirect pathways. The 
prevailing view is that the progressive loss of DA activation of D1 and D2 receptors leads to 
hypoactivity of direct MSNs and hyperactivity of indirect MSNs. Decreased activity of the direct 
pathway results in the disinhibition of basal ganglia output structures GPi/SNr. Meanwhile, increased 
activity of the indirect pathway causes GPe inhibition, resulting in STN disinhibition, which 
exacerbates basal ganglia output structures GPi/SNr signaling (Albin et al., 1989; DeLong, 1990). The 
overall effect leads to an overstimulation of the inhibitory GPi/SNr control of the thalamocortical 
pathway and the brainstem targets, which is presumably responsible for motor symptoms expressed by 
akinesia and bradykinesia in PD patients.  
Previous clinical observations showing that antimuscarinic drugs were the first symptomatic treatment 
of PD patients before the discovery of L-DOPA (Charcot, 1879; Fahn, 1989) led to the hypothesis that 
both cholinergic and dopaminergic signaling systems had to be in balance to allow the striatum to 
function normally to control movement (Barbeau, 1962; McGeer et al., 1961). In PD, anticholinergic 
drugs presumably would reduce the increased striatal cholinergic tone caused by the loss of DA and 
thus partially restore the balance between these two signaling systems (Conti et al., 2018; Langmead et 
al., 2008; Ztaou et al., 2018; 2016). Indeed, it has long been reported that DA and ACh exert opposing 
effects on striatal circuitry (Aosaki et al., 2010; Bonsi et al., 2011; Conti et al., 2018; Lester et al., 
2010; Lim et al., 2014; Perez-Lloret and Barrantes, 2016; Pisani et al., 2007; Rizzi and Tan, 2017). 
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However, whether and how the cholinergic disruption of striatal properties contributes to motor and 
non-motor symptoms as DA level falls and affects basal ganglia circuitry remain open questions. 
Moreover, this classical view has been challenged recently in a review reporting that these two 
neurotransmitters could also work in concert with one another to create patterns of activity in the 
striatum crucial for the control of movement (Tanimura et al., 2018).  
 
Dopamine-acetylcholine balance in physiological condition 
The balance between dopaminergic and cholinergic systems is crucial to modulate the striatal circuitry 
for the control of movement in the physiological state. Indeed, ChIs activity is modulated by DA 
projections originating from the SNc and ventral tegmental area (VTA). Direct MSNs are activated by 
DA action on D1 receptors and inhibited by ACh action on M4 mAChRs. In contrast, indirect MSNs 
are inhibited by DA action on D2 receptors but activated by ACh action on M1 mAChRs (Bonsi et al., 
2011; Gerfen and Surmeier, 2011; Goldberg et al., 2012; Kreitzer, 2009; Oldenburg and J. B. Ding, 
2011; Pisani et al., 2007; Rizzi and Tan, 2017). Hence, dopaminergic and cholinergic transmissions 
modulate the functional balance between the direct and indirect pathways and consequently the correct 
execution of movement. 
Dopaminergic control of ACh release depends on dopaminergic receptors expressed by ChIs. All ChIs 
express D2 receptors while only a small proportion of them express D1 receptors (Gonzales and Y. 
Smith, 2015, Lim et al., 2014). Several in vitro and in vivo studies show that DA exerts an inhibitory 
control on ChIs via D2 receptors and induces a decrease of ACh release (Consolo et al., 1993; DeBoer 
and Abercrombie, 1996; Lehmann and Langer, 1983; Pisani et al., 2000; Stoof et al., 1992; Yan et al., 
1997). On the contrary, in absence of D2 receptors, DA acts on D1 receptors and increases ACh 
release (Acquas and Di Chiara, 1999; Damsma et al., 1991; DeBoer and Abercrombie, 1996; Di 
Chiara et al., 1994; Steinberg et al., 1998). 
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Cholinergic control of DA release is dependent upon the activation of presynaptic nAChRs and 
mAChRs modulation (Acquas and Di Chiara, 2002; Aosaki et al., 2010; Exley and Cragg, 2008; 
Goldberg et al., 2012; Kreitzer, 2009; Oldenburg and J. B. Ding, 2011; Threlfell and Cragg, 2011). 
Recent studies showed that optogenetic activation of ChIs generates a local release of DA in the 
striatum, via the activation of presynaptic nAChRs expressed on dopaminergic terminals (Threlfell et 
al., 2012; Wang et al., 2014). Cachope et al. reported that the effect of ChIs activation on DA release 
is only partially mediated by the activation of nAChRs (Cachope et al., 2012). Indeed, the combination 
of optogenetic and pharmacological in vitro approaches demonstrate a concomitant action of ACh on 
β2-containing nAChRs and mAChRs, together with an inactivation of AMPA receptors. 
There is evidence of a predominant expression of mAChRs in the ventral striatum in comparison to 
the dorsal striatum in rodents (Tayebati et al., 2004; Threlfell and Cragg, 2011). In the dorsolateral 
striatum, both types of cholinergic receptors are involved in the regulation of DA release, whereas in 
the dorsomedial striatum mAChRs have a predominant role (Gauchy et al., 1991). M1 mAChRs-
knockout mice exhibit increased DA release in the striatum (Gerber et al., 2001). As dopaminergic 
terminals do not express M1 mAChRs, cholinergic modulation has been suggested to indirectly affect 
DA transmission in the striatum by an action on M1 mAChRs expressed on a subset of MSNs that 
project directly to the SNc and inhibit dopaminergic neurons. In the absence of M1 receptors, the loss 
of this inhibitory control of dopaminergic neurons produces greater discharge activity and elevation of 
striatal DA release (Gerber et al., 2001). Other studies using M2 mAChRs-knockout mice or M4 
mAChRs-knockout mice suggest that they are involved in the DA-ACh balance in the striatum and are 
crucial in motor control (Gomeza et al., 1999a; 1999b; Salamone et al., 2001; Wess et al., 2007). In 
these mutant mice, an exacerbated dopaminergic transmission is also observed. The loss of 
autoreceptors function on ACh release results in a net increase in striatal ACh, which then activates 
nAChRs expressed in the dopaminergic terminals (Pisani et al., 2007; Wess et al., 2007). 
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In the striatum, neuropeptides such as tachykinins (substance P, neurokinins A and B) and opioids 
(enkephalins and dynorphins) expressed by MSNs play also a crucial role in the DA-ACh balance. 
When these peptides are released by MSNs collaterals, they regulate dopaminergic (Di Chiara and 
Imperato, 1988; Dourmap et al., 1997; Kemel et al., 1992; Krebs et al., 1994; Li et al., 2002; Tremblay 
et al., 1992) and cholinergic transmission in the striatum (Arenas et al., 1991; Blanchet et al., 1998; 
Jabourian et al., 2004; Steinberg et al., 1998). Indeed, direct MSNs co-express substance P with 
GABA and form synaptic connections with ChIs. By stimulation of NK1 receptors expressed in ChIs, 
Substance P induces a release of ACh (Lim et al., 2014). In contrast, enkephalins co-expressed with 
GABA in indirect MSNs exert an inhibitory control of ACh release via μ opioid receptors (MORs) 
expressed in ChIs. Inhibition of ACh, via MORs activation, induces a decrease of DA release in the 
striatum, presumably by limiting presynaptic activation of nAChRs (Britt and McGehee, 2008). 
Electrophysiological recordings in non-human primates display distinct but coincident reward-
related activity in DA neurons and ChIs during performance on an instrumental conditioning 
task (Cragg, 2006).  DA neurons signal reward-predicting or unexpected events by a phasic 
burst or pause in firing rate associated with reward presentation or omission, respectively, while 
ChIs always display a pause in firing rate following reward-related events (Aosaki et al., 2010; 
1994; Apicella et al., 1997; Morris et al., 2004; Zhang and Cragg, 2017). The pause response of 
ChIs actually consists of triphasic response which begins with an initial excitation, followed by a 
pause and a rebound excitation (Aosaki et al. 2010; Morris et al., 2004). DA neurons and ChIs 
responses are ‘time-locked’: when DA neurons are recorded in the same learning conditioning 
task, their reward-related bursts occur with similar latency and duration than ChIs response 
(Morris et al., 2004). Although the precise mechanisms contributing to the pause response of ChIs 
are still being investigated, it requires both the nigrostriatal dopaminergic projections and the 
thalamostriatal glutamatergic projections to occur, as the pause response disappears if either projection 
is interrupted (Aosaki et al., 1994; Reynolds and Wickens, 2004; Zhang and Cragg, 2017). 
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Disruption of the dopamine-acetylcholine balance in Parkinson’s disease 
In non-human primates, unilaterally injected with a selective neurotoxin of dopamine neurons 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and trained in a classical conditioning task, responsive 
TANs were dramatically decreased in the depleted striatum, whereas cells in the intact side remained 
responsive (Aosaki et al., 2010; 1994). This evidence suggests that there is close relationship between 
ChIs activity and DA neuronal firing, ultimately altered in parkinsonian state. 
In the 6-hydroxydopamine (6-OHDA) lesion model of PD, microdialysis studies showed that striatal 
ACh levels are elevated in the DA-depleted rat striatum (DeBoer et al., 1993), indicating a deregulation 
of ChIs excitability in vitro (Fino et al., 2007; Maurice et al., 2015). The increased striatal ACh level 
was attributed to the loss of inhibitory control mediated by D2 receptors on ChIs (Maurice et al., 2004). 
However another study indicates that it could also be due to a reduction in the efficacy of M4 mAChRs 
autoreceptors (through downregulation of RGS4 expression, an autoreceptor-associated, GTPase-
accelerating protein) and this would consequently increase ACh signaling (J. J. Ding et al., 2006). Given 
the therapeutic effects of anticholinergic drugs in PD mentioned above, and the physiological changes in 
ChIs seen in animals models of the disease, it is evident that DA-ACh imbalance is crucial to the 
expression of parkinsonian-like symptoms (Brichta et al., 2013; Kalia et al., 2013; Langmead et al., 
2008; Maurice et al., 2015; Ztaou et al., 2018; 2016). 
In DA-depleted rats, there is also evidence of synaptic reorganization of striatal ChIs within the striatum 
following intranigral 6-OHDA injection (Salin et al., 2009). Salin et al. used retrograde transynaptic 
spread of rabies virus injected into the GPe or SNr to identify the strength of ChIs connection onto 
either direct or indirect MSNs. In normal condition, ChIs provide equivalent input onto direct or indirect 
MSNs. In parkinsonian state, however, there is a switch of cholinergic innervation onto indirect MSNs, 
which could contribute to the imbalanced striatal outflow. Recent studies using optogenetics support the 
central role of striatal ChIs activity in the reorganization of striatal microcircuitry and the production of 
motor symptoms in PD condition (Conti et al., 2018; Lester et al., 2010; Pisani et al., 2007; Rizzi and 
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Tan, 2017). Indeed, optogenetic photoinhibition of ChIs in DA-depleted mice following unilateral 6-
OHDA lesions improves PD-like motor symptomatology by reducing akinesia, bradykinesia, and 
sensorimotor neglect (Maurice et al., 2015; Ztaou et al., 2016). Interestingly, positive effects of ChIs 
photoinhibition are also observed on cognitive and affective alterations (anxiety, visuospatial short-term 
memory) induced by partial striatal DA depletion, mimicking the premotor phase of PD (Ztaou et al., 
2018), suggesting that the DA-ACh imbalance may also be present in the early stages of the disease. In 
addition, striatal ChIs appear to be crucial to the expression of L-DOPA-induced dyskinesia and 
optogenetic activation of striatal ChIs regulates their expression (Bordia and Perez, 2018; Bordia et al., 
2016).  
Dopaminergic depletion also induces an alteration of neuropeptide expression (tachykinins, opioids) in 
the striatum and thus of striatal cholinergic transmission leading to an imbalance of the DA-ACh 
interaction. In DA-depleted rats, tachykinin increases cholinergic transmission in the sensorimotor 
(Kemel et al., 2002) and limbic (Pérez et al., 2007) territories of the striatum. Moreover, in the absence 
of dopaminergic transmission, enkephalins via μ opioid receptors (MORs) expressed by ChIs inhibit 
ACh release in the limbic regions of the striatum (Jabourian et al., 2007). Hence, an alteration of the 
regulation of cholinergic transmission, via enkephalins and MORs, play a role in cognitive and 
motivational deficits associated with PD in rodent parkinsonian model. 
In addition to alteration in ChIs signaling, M2 and M4 mAChR subtypes, and nAChRs expression are 
also affected in PD (Aubert et al., 1992; Bohnen and Albin, 2011; Brown and Marsden, 1990; Lang and 
Lozano, 1998a; 1998b; Müller and Bohnen, 2013). A loss of M2 mAChRs has been shown in a genetic 
model for PD, the Pitx3
ak/ak
 mice (Cremer et al., 2015). Conflicting studies show that M4 mAChRs 
expression may be either decreased or enhanced in parkinsonian states. The loss of DA innervation has 
been reported to attenuate M4 mAChRs expression in ChIs, which might be a main factor in the 
elevated striatal ACh signaling after DA depletion (J. J. Ding et al., 2006). On the other hand, other 
studies indicate that M4 mAChRs activation contributes to PD symptoms. Salamone et al. showed that 
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central-acting M4 mAChRs antagonist and M4 mAChRs-knockout mice reduce tremulous jaw 
movements in a pharmacological rat model of dyskinesia in PD (Salamone et al., 2001). M4 mAChRs 
antagonism also alleviate motor deficits such as akinesia, bradykinesia, and sensorimotor neglect in the 
6-OHDA mice model of PD (Ztaou et al., 2016). The anti-parkinsonian effects of the M4 mAChRs 
antagonist tropicamide have been shown to be almost completely abolished in mutant 6-OHDA-lesioned 
mice lacking M4 mAChRs specifically in direct MSNs (D1-M4-knockout mice). This suggests that the 
beneficial effects of M4 mAChRs antagonism on motor symptoms is the consequence of a postsynaptic 
M4 mAChRs expressed on direct MSNs blockade rather than a presynaptic blockade of M4 mAChRs 
located on ChIs (Ztaou et al., 2016). 
The loss of dopamine is associated with a widespread loss of nAChRs expression in PD (Aubert et al., 
1992; Bohnen and Albin, 2011; Müller and Bohnen, 2013). An estimated 50-90% loss of nigrostriatal 
nAChRs expression is observed after DA depletion in experimental models and clinical populations 
(Conti et al., 2018). A post-mortem in vitro study using a nAChRs ligand demonstrated a loss of 
nAChRs specifically in the striatum concomitantly to the loss of nigrostriatal dopaminergic markers 
(Pimlott et al., 2004). In vivo imaging studies of PD patients have also reported a reduction of α4β2 
nAChRs expression in the striatum (Fujita et al., 2006; Kas et al., 2009). The loss of nAChRs containing 
α6β2 tends to be more severe than that of those containing α4β2 since α6β2-containing nAChRs are 
selectively located on nigrostriatal terminals (Conti et al., 2018; Perez, 2015; Perez et al., 2010). 
Whether these impairments are the cause or the consequence of DA loss in PD, targeting cholinergic 
receptors offers potential therapeutic application to normalize the striatal DA-ACh balance and thus, 
treat parkinsonian symptoms. 
 
Potential targets for Parkinson’s disease treatment 
As mentioned above, as striatal DA levels fall in PD, the cholinergic tone rises (Barbeau, 1962; 
Duvoisin, 1967; Hornykiewicz and Kish, 1987). This elevation is clinically important, as antagonizing 
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mAChRs – which appears to be the highest concentration of cholinergic receptors found in the striatum 
(Cortes and Palacios, 1986; Cortes et al., 1986) – might effectively reverses many motor (and non-
motor) symptoms of PD (Bonsi et al., 2011; Ferreira et al., 2013; Langmead et al., 2008; Pisani et al., 
2007; Rascol et al., 2011; Rezak, 2007; Y. Smith et al., 2012). 
Charcot was the first, in 1879, to note the beneficial effects of belladonna alkaloids (agents with potent 
anticholinergic properties) containing atropine on the parkinsonian motor signs. They were effective on 
rigidity and tremor, potentially exerting their effects by preventing ChIs overactivity (Barbeau, 1962; 
Hornykiewicz and Kish, 1987). However, anticholinergic drugs do not alleviate akinesia or 
bradykinesia. Moreover, they produce side-effects including urinary retention, nausea, falls, and 
drowsiness. Cognitive impairment affecting learning and memory processes, as well as cognitive 
flexibility may also be produced by anticholinergic drugs presumably caused by the decrease of ACh 
tone in frontal cortical areas during the course of the disease (Ferreira et al., 2013; Rascol et al., 2011; 
Rezak, 2007). Anticholinergics remained the only drugs available for the symptomatic treatment of PD 
for nearly a century until the introduction of L-DOPA. Nowadays, anticholinergics drugs are prescribed 
if tremor persists (Ferreira et al., 2013) and only to relatively young patients in the early stages of PD or 
for those who do not respond to DA replacement therapy (Yamada et al., 2002).  
Despite the fact that anticholinergic drugs are accompanied by troublesome side effects, impairment of 
striatal ChIs activity could be pharmacologically manipulated by targeting the multitude of cholinergic 
receptor subtypes expressed in the striatal circuitry. Thus, their potential therapeutic relevance warrants 
further research to obtain more selective agents (Pisani et al., 2007). Whether the discovery of selective 
antagonists, more precisely targeting a mAChRs subtype, will provide better treatment for parkinsonian 
rigidity and tremor without the side effects remains to be investigated (Langmead et al., 2008). 
In pharmacology, it is generally considered easier to develop subtype selective antagonists than 
agonists. In animal models and early stage of PD, blocking mAChRs, more precisely M1 and M4 
mAChRs, has been shown to improve parkinsonian motor deficits (Betz et al., 2007; Xiang et al., 2012; 
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Ztaou et al., 2016). Mice lacking M1 mAChRs (M1 mAChRs-knockout mice) exhibit an elevated 
locomotor activity and an exacerbated dopaminergic transmission in the striatum, suggesting that 
blocking M1 mAChRs might be an alternative strategy for alleviating motor symptoms (Gerber et al., 
2001). However, M1 mAChRs blockade has been associated with puzzling effects on non-motor 
symptoms in PD. Studies show that antagonizing M1 mAChRs impairs working memory, memory 
consolidation and behavioral flexibility (Anagnostaras et al., 2003; Ragozzino et al., 2002; Tzavos et al., 
2004). On the contrary, the selective M1 mAChRs antagonist, telenzepine, injected at low dosage 
reduce mood disorders such as anxiety-like behavior (Ztaou et al., 2018). 
M4 mAChRs antagonists may also be used to restore the DA-ACh balance in PD and thus improve 
motor symptoms. Studies show that M4 mAChRs antagonists could be potential antiparkinsonian agents 
to alleviate pilocarpine-induced tremulous jaw movements in rats (Mayorga et al., 1999) and 
akinesia/bradykinesia in 6-OHDA mice (Ztaou et al., 2016). Gomeza et al. show that mice lacking M4 
mAChRs (M4 mAChRs-knockout mice) exhibit an elevated basal locomotor activity (Gomeza et al., 
1999b). A review describing recent progress made in mAChRs drug discovery promotes the use of 
selective M4 mAChRs antagonists to address the parkinsonian tremor and rigidity and M1 mAChRs 
agonists to treat cognitive deficits (Langmead et al., 2008).  
In summary, investigation of highly selective components and translation into clinical use remains a 
challenge. Normalizing ChIs signaling, by targeting cholinergic receptors, is a crucial therapeutic goal 
for a multisystem disorder like PD. However modulating striatal ACh to alleviate either motor 
symptoms or non-motor symptoms of PD across the disease progression may require multi-faceted 
treatment across the disease progression. 
 
Concluding remarks 
The advances in the experimental tools (optogenetic and chemogenetic techniques, new recording 
techniques, highly selective mAChRs compounds) have shed light on the function of ChIs in 
physiological and pathological conditions.  
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The ability of ChIs to release other neurotransmitters like glutamate, in addition to ACh itself, 
has been increasingly described in recent reviews (Kljakic et al., 2017; Mestikawy et al., 2011; 
Trudeau and Mestikawy, 2018). A study shows that glutamate via the vesicular glutamate 
transporter type 3 (VGLUT3) plays also an important role in the development of L-DOPA-
induced dyskinesia (Gangarossa et al., 2016). Furthermore, these two co-transmitters exert 
opposing effects on DA release. DA efflux is stimulated by nAChRs and inhibited by VGLUT3- 
dependent glutamate (through metabotropic glutamate receptors, mGluRs, most likely located on 
DA terminals) (Sakae et al., 2015). Although the co-release ACh/glutamate and the nAChRs 
regulation are not central in this review, these two points need to be considered in the regulation 
of striatal network.  
Moreover, DA inputs regulate ChIs differently across dorsal striatal regions. Two recents studies 
reported that DA neurons drive pauses in the firing of dorsomedial ChIs but bursts in 
dorsolateral ChIs (Cai and Ford, 2018; Chuhma et al., 2018). These variations are due to different 
actions of DA/glutamate cotransmission and encompass once more the complexity of DA-ACh 
balance regulation in the striatum. 
In this review, we discuss the long-standing model that DA and ACh oppose one another. There 
are still compelling evidence of opposite effects of these two neurotransmitters in striatal 
microcircuitry regulation. However, this view has been revised also suggesting a cooperation 
between DA and ACh, that indicates a more complex interaction between these two neuronal 
systems (Surmeier and Graybiel, 2012, Threlfell et al., 2012). 
It is clear that cholinergic signaling plays a major role in modulation of striatal microcircuitry and basal 
ganglia output. ChIs undergo major changes during PD that will be more and more investigated in the 
future years, as well as in other basal ganglia diseases (e.g. dystonia, Tourette syndrome, Huntington’s 
disease). The development of novel anticholinergic drugs, more selective of mAChR subtypes, may help 
to avoid the major side-effects associated with classical anticholinergic treatment. Novel wireless 
implantable micro-scale devices will allow the use of optogenetics to target specific neural circuits, like 
ChIs, in experimental models of these diseases and probably in the future will provide new therapeutic 
strategies.   
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Figure 1 
Cholinergic modulation of the striatal microcircuitry. Simplified diagram of the interactions among the 
different types of striatal neurons – cholinergic interneuron (red), direct/indirect MSNs (yellow), 
GABAergic interneuron (blue) – and glutamatergic (orange) and dopaminergic (green) afferents to the 
striatum. The illustration reports the widespread distribution of muscarinic acetylcholine receptors 
(mAChRs: M1, M2, M3, M4), nicotinic acetylcholine receptors (nAChRs), and dopamine receptor 
subtypes (D1, D2). G protein-coupled receptors are displayed with their associated G-protein: Gs, Gi, or 
Gq. The diversity of mAChRs and nAChRs and their localization highlight the complexity of 
cholinergic modulation in the striatum. Abbreviations: ACh, acetylcholine; DA, dopamine; GABA, 
Gamma-aminobutyric acid, Glu, glutamate; MSN, medium spiny neuron. 
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